Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $143,371 | $20,208,660 | $774,117 | $774,117 |
| - Cash | $96,621 | $34,647 | $37,735 | $76,067 |
| + Debt | $8,242 | $9,079 | $10,564 | $5,555 |
| Enterprise Value | $54,992 | $20,183,092 | $746,946 | $703,605 |
| Revenue | $0 | $0 | $7,025 | $5,656 |
| % Growth | – | -100% | 24.2% | – |
| Gross Profit | -$2,133 | -$1,707 | $7,025 | $5,656 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$125,202 | -$58,472 | -$27,777 | -$25,761 |
| % Margin | – | – | -395.4% | -455.5% |
| Net Income | -$127,477 | -$60,366 | -$28,893 | -$26,350 |
| % Margin | – | – | -411.3% | -465.9% |
| EPS Diluted | -3.33 | -0 | -1.12 | -1.02 |
| % Growth | -3,329,900% | 100% | -9.8% | – |
| Operating Cash Flow | -$114,250 | -$52,410 | -$36,113 | -$22,155 |
| Capital Expenditures | -$2,205 | -$621 | -$768 | -$1,289 |
| Free Cash Flow | -$116,455 | -$53,031 | -$36,881 | -$23,444 |